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Abstract
Background: Antiretroviral treatment (ART) has altered the spectrum of HIV-related eye disease, resulting in a lower
prevalence of retinal opportunistic infections (OIs). However, abnormalities in visual function have been reported in HIV-
infected individuals despite effective viral suppression and the absence of retinal OIs. These changes may be mediated by
an HIV-associated ‘neuroretinal disorder’, characterized by changes in the retinal nerve fibre layer (RNFL). HIV infection may
also be associated with accelerated biological aging. The aim of this study was to investigate the relationships between
contrast sensitivity, RNFL thickness, HIV infection and frailty in South African adults.
Methods: Case-control study of 225 HIV-infected individuals without retinal OIs and 203 gender/age-matched HIV-
seronegative individuals. Peri-papillary RNFL thickness was determined with spectral domain optical coherence tomography
in four quadrants. CS was measured using a Pelli-Robson chart. Frailty was assessed using standard criteria. Multivariable
linear and logistic regression were used to assess associations between HIV status and RNFL/CS and frailty.
Results: The median age of both groups was similar (41.2 vs. 41.9 years, p = 0.37). 88% of HIV-infected individuals were
receiving ART and their median CD4 count was 468 cells/ml. Adjusted CS score was lower in HIV-infected participants
compared to HIV-seronegative individuals (1.76 vs. 1.82, p = 0.002). Independent predictors of poor CS in the HIV-infected
group were positive frailty status and current HIV viral load .2 log copies/ml. Lower CS score was also associated with thin
temporal RNFL in HIV-infected individuals (p = 0.04). Superior quadrant RNFL thickness was greatest in ART-naı¨ve
participants relative to the HIV-uninfected group (p-trend = 0.04). Longer ART duration was associated with thinning of
inferior and nasal RNFL quadrants (p-trend = 0.03 and 0.04, respectively).
Conclusions: Contrast sensitivity is reduced in HIV-infected individuals and functionally associated with frailty and
unsuppressed viraemia. This may reflect structural changes in the RNFL that are evident despite the absence of OIs.
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Introduction
In well-resourced settings, antiretroviral treatment (ART) has
altered the spectrum of HIV-related eye disease in people living
with HIV infection, leading to a lower prevalence of retinal
opportunistic infections (OIs) such as cytomegalovirus (CMV)
retinitis [1,2]. This trend is now becoming apparent in resource-
constrained environments where scale-up of ART is commenced
in individuals with increasingly high CD4 counts. However,
abnormalities in visual function, such as reduced contrast
sensitivity (CS), altered colour vision and visual field loss have
also been reported in HIV-infected individuals despite effective
viral suppression and the absence of retinal OIs. It is thought that
these changes may be mediated by an HIV-associated ‘neuror-
etinal disorder’ (HIV-NRD) which is characterized by changes in
the retinal nerve fibre layer (RNFL) [3–5].
One mechanism that may potentially contribute to HIV-NRD
is ‘accelerated biological’ aging that is recognised to be associated
with HIV infection [6]. This refers to conditions which are
classically associated with the normal aging process but which
occur at an earlier age in HIV-infected individuals compared with
those of similar age who are seronegative [7–9]. This may have
major implications for long-term morbidity, including for the
many millions of people receiving ART in sub-Saharan Africa
[10,11]. However, there are limited data on visual function (in the
absence of ocular OIs) in people living with HIV in this region.
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Although RNFL changes are strongly related to chronological age
[12,13], studies describing visual function, RNFL status and the
possibility of HIV-NRD in HIV-infected individuals are needed,
particularly as quality of life might be significantly compromised.
Indeed, impaired contrast sensitivity (CS) can be more disabling
than visual acuity loss [14].
We have recently undertaken a case-control study of adults in
South Africa, and have shown that HIV infection is associated
with several ocular changes i.e. in retinal vessel calibre, lens density
and corneal endothelial cell density consistent with accelerated
HIV-related aging [15–17]. We have also shown in the same study
population that HIV infection is associated with a functional
phenotype consistent with frailty [6]. This is a clinical syndrome
initially described in geriatric populations, characterised by
multiple pathologies, low physical activity and slow motor
performance [18,19]. Frailty predicts cognitive and physical
decline and is associated with an increased risk of morbidity and
mortality. We now report the findings of visual function from this
study, using CS and RNFL as representative measures of ocular
aging. The objectives of this study were to assess differences and
identify predictors of CS and RNFL parameters in HIV-infected
individuals compared to age-gender matched controls, and to
assess whether visual function is related to the phenotype
consistent with HIV-related accelerated biological aging that we
have already reported.
Methods
Ethics statement
The study was approved by the Ethics Committees of the
London School of Hygiene and Tropical Medicine and the
University of Cape Town Faculty of Health Sciences, and adhered
to the tenets of the Declaration of Helsinki. Written informed
consent was obtained from all participants.
Study participants
HIV-infected participants aged .30 years were enrolled from
a community-based HIV treatment centre in Nyanga district in
Cape Town [20,21]. Participant recruitment has been reported
in detail previously [6]. In brief, all participants had a confirmed
serological diagnosis of HIV and were either about to commence
ART (ART-naı¨ve), or were already on first-line ART. Individuals
were excluded if they had a history or current ocular OI, which
was confirmed from medical case notes. All participants had a
best-corrected visual acuity of 20/40 or better in order to be able
to perform ophthalmic tests (i.e. CS) satisfactorily. A control
group of HIV-seronegative participants was recruited from an
HIV clinical prevention trials centre in a neighbouring commu-
nity by frequency-matching using gender and 5-year age
categories.
Data collection
Data on age, sex, weight and height, as well as socio-
behavioural factors such as housing, income, smoking and alcohol
consumption were collected. Data collected for HIV-infected
participants included nadir and current CD4 count, peak and
current viral load, staging of HIV according to WHO clinical
stage, ART status and regimen. Clinical information was obtained
from medical case notes as required. Blood pressure (BP) was
measured with a digital sphygmomanometer with a cuff of
appropriate size. Mean arterial blood pressure (MABP) was
defined as two-thirds of the diastolic plus one-third of the systolic
BP [22]. Hypertension was defined as a systolic BP of 140 mmHg
or higher, diastolic BP of 90 mmHg or higher, or the combination
of self-reported high BP diagnosis and the use of anti-hypertensive
medications [23]. Body mass index (BMI) was defined as weight (in
kilograms)/height2. In brief physical frailty was defined by the
presence of $3 of 5 criteria: i) unintentional weight loss (self
reported and verified from clinic records where possible) ii) self-
reported low physical activity, iii) self-reported exhaustion, iv)
weak grip strength and v) slow walking time. Detailed assessment
of frailty within this study population has been previously reported
[6].
All participants underwent a full ophthalmic examination
including measurement of visual acuity, evaluation by slit lamp
microscopy and indirect ophthalmoscopy. Contrast sensitivity was
measured with a Pelli-Robson chart under ambient (daylight)
conditions as per the recommendation of the manufacturer (Haag-
Streit, Essex, UK). All examinations were conducted in the same
room under the same lighting conditions. The chart has eight lines
of letters with two groups of three letters per line. Testing was
performed at 1 m with a 0.75 diopter lens added to the manifest
refraction if necessary. The logarithm to the base 10 of the CS
measurement was obtained from the Pelli-Robson chart and used
in analyses (LogCS). Investigators who conducted the tests were
masked to other data. RFNL thickness was obtained using the
Spectral OCT/SLO optical coherence tomography machine
(Opko/OTI Inc, Miami, FL). OCT scans were performed by
one trained operator to reduce inter-observer variation. Only
OCT scans that were of sufficient quality (signal 70% of maximum
strength, absence of imaging artefacts, or distortions) were used.
Replicates were only taken if the OCT scans were of insufficient
quality. The Spectral OCT/SLO uses a scanning laser diode of
830 nm to provide images of ocular microstructures. A peripap-
illary protocol inbuilt in the software was used to determine the
average and quadrant-specific RNFL thickness (superior, inferior,
temporal and nasal).
Statistical analyses
One eye was randomly selected for analysis. Where an eye was
not available, for example due to trauma or corneal opacity, the
contralateral eye was used. LogCS scores and RNFL were initially
analysed as continuous variables. Age and sex-adjusted linear
regression was performed to compare logCS score and RNFL
parameters respectively by HIV status. A binary categorisation of
logCS was defined using the a-priori defined cutpoint of the 25th
percentile in the control group to denote ‘poor CS’ (1.65). Further
analyses were undertaken using the cut-off of 1.50 as defined by
Shah and associates [24]. Similarly, a binary categorisation of
RNFL was defined using the cut-off of the 25th centile in the
control group to denote ‘thin RNFL’ (#25th percentile; average
101 mm, superior 118 mm, inferior 124 mm, temporal 62 mm,
nasal 74 mm). Logistic regression was used to assess predictors of
poor CS in those participants on ART. Multivariable linear
regression models were used to examine the relationship of RNFL
parameters as the dependent variable, with HIV status and other
explanatory variables (age group [30–39; 40–49; .50 years],
gender, MABP; BMI, smoking) as independent variables. Separate
models were used for HIV-infected participants to investigate the
effects of HIV-related variables. Marginal adjusted means for
RNFL parameters were estimated at the mean value of covariates
in the model. The Wald test was used to assess statistical
significance of the association of each explanatory variable on
RNFL thickness. All analyses were performed with Stata 12 (Stata
Corp, College Station, TX).
RNFL and Contrast Sensitivity in HIV Infection
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Results
Participant characteristics
Characteristics of the 225 HIV-infected individuals and 203
HIV-seronegative age/gender frequency matched HIV-seronega-
tive individuals are reported in Table 1. Although frequency
matching was undertaken, some individuals did not have OCT
images of adequate quality for analysis, resulting in a greater
proportion of HIV-infected participants being included in the
analyses. However, those with images did not differ from those
without with respect to age, gender or other clinical/demographic
characteristics (p.0.10 for all variables; data not shown). HIV-
infected participants tended to have a greater income (attributable
to a government health-related grant), be non-smokers, report
lower consumption of alcohol and have a lower BMI than HIV-
seronegative individuals. There was little difference in visual acuity
Table 1. Characteristics of study participants.
Variable HIV-infected HIV-seronegative P-value**
2225 2203
Age (mean 6 SE) 41.260.5 41.960.6 0.37
N % N %
Age, years by group
30–39 112 49.7 98 48.3
40–49 73 32.4 65 32 0.88
.50 40 17.8 40 19.7
Gender
Male 60 26.7 49 24.1
Female 165 73.3 154 75.9 0.55
Income
,ZAR1000/month 128 56.9 140 69 0.01
.ZAR1000/month 97 43.1 63 31
Smoking status
Non-smoker 190 84.4 146 71.9 0.002
Smoker 35 15.6 57 28.1
Alcohol consumption
No 156 69.3 112 55.2 0.002
Yes 69 30.7 91 44.8
Hypertension*
No 144 64 122 60.1 0.41
Yes 81 36 81 39.9
Body mass index (kg/height2) 28.060.4 31.960.6 0.0001
Visual acuity (presenting) (median) 20/20 20/20 0.34
(20/20–20/25) (20/20–20/32)
WHO stage N % or median (IQR)
2-Jan 62 27.6
4-Mar 163 72.4
ART naı¨ve 27 12
CD4 count in ART naı¨ve group 27 170 (81–201)
Log10VL in ART naı¨ve group 16 4.79 (4.07–5.09)
Current CD4 count in ART group 468 (327–607)
Nadir CD4 count in ART group 136 (77–175)
% with detectable VL in ART group 30 15.1
Peak Log10VL in ART group 4.47 (3.74–4.97)
Duration of ART, months 198 56.5 (34–74)
ART Regimen
Containing AZT/3TC 118 59.6
Other 80 40.4
*Hypertension defined as a systolic BP of 140 mmHg or higher, diastolic BP of 90 mmHg or higher, or the combination of self-reported high BP diagnosis and the use of
anti-hypertensive medications.
**P-value obtained by t-test or x2 –test as appropriate.
doi:10.1371/journal.pone.0073694.t001
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between the two groups. Among the HIV-infected participants,
88% of whom were receiving ART, the current median CD4
count was 468 cells/mL (interquartile range: [IQR]: 327–607) and
84.9% had an undetectable plasma viral load (VL), defined as,50
copies/ml.
Contrast sensitivity
Data on CS were available for 216 HIV-infected individuals
and 215 HIV-seronegative individuals. Unadjusted mean logCS
was lower in HIV-infected individuals compared to HIV-
seronegative participants (1.77 vs. 1.82, p = 0.005) (Standard
deviation and min/max values 0.22; 1.00–1.95 HIV-uninfected;
0.18; 1.20–1.95 HIV-infected). After adjustment for age, sex,
smoking status (yes/no), MABP and BMI, mean logCS values still
remained lower in HIV-infected individuals (1.76 vs. 1.82,
p = 0.002). HIV-infected individuals were also more likely to have
‘poor CS’ (,1.65) compared to their uninfected counterparts
(adjusted proportions: 43.5 vs. 31.8%, p = 0.01 – adjusted for age,
gender, smoking status).
In multivariable analysis among HIV-infected participants on
ART, poor CS was associated with positive frailty status (OR 3.04;
95%CI: 1.25–7.35, p = 0.01) (Table 2) and HIV viral load .2 log
copies/ml (OR 3.03; 95%CI: 1.02–8.97, p = 0.05).
Table 2. Predictors of poor contrast sensitivity among HIV-infected participants on ART (N = 190) using logistic regression analysis.
Variable Odds ratio (OR) P-value
For reduced contrast sensitivity (from likelihood ratio test; LRT)
Age group
30 years 1
per 10 year increase 1.22 (0.75–2.00) 0.43
Sex
Male 1
Female 1.73 (0.66–4.57) 0.27
Frailty status
Not frail 1
Frail 3.04 (1.25–7.35) 0.01
Smoking status
Non-smoker 1
Current 0.49 (0.17–1.45) 0.2
Current CD4 count
,400 cells/ml 1
.400 cells/ml 0.84 (0.40–1.77) 0.64
Nadir CD4 count
,100 cells/ ml 1
100–200 cells/ ml 1.66 (0.79–3.50) 0.28
.201 cells/ml 2.30 (0.69–7.63)
Current viral load
,2 log copies/ml 1
.2 log copies/ml 3.03 (1.02–8.97) 0.05
Peak viral load
,4.5 log copies/ml 1
.4.5 log copies/ml 0.85 (0.43–1.68) 0.64
WHO clinical stage
2-Jan 1
4-Mar 1.84 (0.78–4.32) 0.17
ART duration (months)
,24 1
25–48 2.28 (0.74–7.08)
49–72 2.73 (0.85–8.75) 0.3
.73 1.68 (0.50–5.61)
ART regimen
Containing AZT/3TC 1
Other 1.20 (0.61–2.34) 0.6
*adjusted for all variables in table, and mean arterial blood pressure and BMI, age group used as a linear term in model.
doi:10.1371/journal.pone.0073694.t002
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Retinal nerve fibre layer
Table 3 shows the average and quadrant RNFL thickness
stratified by HIV status and by viral load status. Average RNFL
thickness was similar between two groups as stratified by HIV
status (yes; no) (109.760.8 mm in HIV-infected participants, vs.
108.760.9 mm in HIV-seronegative individuals, p = 0.41) There
was a trend of greater RNFL thickness of the superior quadrant
with greater HIV viremia: the mean superior RNFL thickness in
HIV-seronegative individuals was 132.2 mm, compared to
133.8 mm in HIV-infected individuals on ART with non-
detectable VL, and 140.0 mm in HIV-infected individuals who
were ART-naı¨ve (and had detectable VL), p-trend = 0.04. A
similar trend was observed for the inferior quadrant (p-
trend = 0.13). Associations of RNFL thickness with current or
nadir CD4 count were not observed.
Among HIV-infected participants increasing age was, as
expected, associated with thinning of the RNFL. Increasing
duration of ART was associated with reduced thickness of the
RNFL in inferior and nasal quadrants (Table 4 and Figures 1 and
2). No association was detected with type of ART. Average and
superior quadrant RNFL thickness was lower in those with
advanced HIV infection at ART initiation, as defined by WHO
clinical stage 3 or 4.
Table 3. RNFL thickness in mm (standard error) by HIV and viral load status – adjusted for age, gender, mean arterial blood
pressure, smoking status and BMI.
RNFL HIV2 All HIV+ P-valuea On ART On ART ART-naive P-value
b
Thickness in mm
VL,50 copies/
ml
VL.50 copies/
ml (Wald test)
(SE) (n= 168) (n =30) (n=27)
(n =203) (n=225)
Average** 108.7 109.7 0.41 109 111.9 111.3 0.52
20.9 20.8 21 22.4 22.5
Superior 132.2 135.1 0.16 133.8 138.5 140 0.04*
21.5 21.4 21.6 23.8 24.1
Inferior 137.9 135.6 0.27 134.7 137.7 139.5 0.5
21.5 21.4 21.7 24 24.3
Nasal 88.4 91.1 0.19 91.2 89.5 95.1 0.13*
21.5 21.5 21.7 24 24.4
Temporal 72.5 73.1 0.65 73.1 73.3 70.7 0.85
20.9 20.9 21 22.4 22.7
Multivariable linear regression model; marginal adjusted means for RNFL parameters were estimated at the mean value of covariates in the model.
**Limited images in this group; total n = 402 (188/160/28/26).
a – for difference between HIV-infected and HIV-seronegative groups.
b – for difference between HIV-seronegative and HIV groups by viral load status.
*– refers to p-value using test for trend.
doi:10.1371/journal.pone.0073694.t003
Figure 1. Scatterplot showing inferior retinal nerve fibre
thickness (RNFL) vs. antiretroviral treatment duration. Refer to
Table 4 for further information.
doi:10.1371/journal.pone.0073694.g001
Figure 2. Scatterplot showing nasal RNFL vs. antiretroviral
treatment duration. Refer to Table 4 for further information.
doi:10.1371/journal.pone.0073694.g002
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Relationship between CS and RNFL thickness
Finally, we assessed CS score according to RNFL thickness (thin
or normal) in HIV-infected participants. Lower CS was associated
with thin temporal RNFL (1.70; thin RNFL, vs. 1.78; normal
RNFL, p = 0.04); the association of temporal RNFL thickness with
CS is also depicted in Figure 3. Logistic regression to assess the
predictive value of temporal thinning of the RNFL as a risk factor
for poor CS showed that those with thin temporal RNFL had a
three-fold risk of poor CS (#1.5), OR: 3.39 (95%CI: 1.22–9.44,
p = 0.02).
Discussion
This study provides evidence that HIV infection is strongly
associated with poor CS in this South African population. Data
from other regions, particularly the USA, demonstrate evidence of
an HIV-related ‘neuro-retinal disorder’, comprising subtle vision
abnormalities in the absence of opportunistic infections [3–5,24].
However, this has not been investigated in sub-Saharan Africa to
date, where access to ART and the aging HIV-infected population
both continue to increase. In a study population from this region
we assessed both structural and functional components of the
RNFL. Our findings relating to RNFL thickness are novel: higher
levels of HIV viremia were associated with a thicker RNFL,
whereas longer duration of ART was associated with a thinner
RNFL. We also found frailty to be an important predictor of poor
CS. These findings have potentially important implications for
long-term visual function particularly among the expanding HIV-
infected aging population in sub-Saharan Africa.
We have previously demonstrated that HIV infection is
associated with an increased risk of frailty, providing evidence
that this functional phenotype is associated with HIV-related
accelerated aging [6]. The present study builds on these findings,
demonstrating that frailty is an important predictor of poor CS.
This suggests that there may be a visual component to frailty in
HIV infection. This is further corroborated by the finding that
abnormal CS is also independently associated with mortality in
individuals with AIDS [25], and may be a sensitive indicator of
generalized aging [26]. However, the present criteria for frailty
assessment do not contain any visual function indicators. In light of
these findings, a validation study that includes visual function as
another measure of frailty may be warranted. Changes in the
RNFL have been demonstrated in conditions with neuro-cognitive
decline (e.g. Parkinson’s Disease; Alzheimer’s Disease) [27,28] and
a neuro-cognitive component may also contribute to the frailty
phenotype [29,30], as well as HIV-associated neurocognitive
Table 4. RNFL thickness in mm in HIV-infected participants (n = 188).
Retinal nerve fibre layer thickness (mm)
Parameter N Average Superior Inferior Nasal Temporal
mm p-value mm p-value mm p-value mm p-value mm p-value
Age group, years
30–39 95 112 138.3 139.7 89.3 76.6
40–49 61 109.5 ,0.0001* 133.7 0.004* 133.4 0.001* 93.7 0.29 70.6 0.006*
.50 32 102.2 124.9 125.2 88.5 69.3
ART duration, months
,36 55 110.4 136.6 138.5 93 72.3
37–72 83 110.1 135.1 137 93.4 73.2
.73 50 107.7 0.37* 131.4 0.27* 128.6 0.02* 84.1 0.04* 74.5 0.81
WHO clinical stage
2-Jan 42 112.5 141.1 139.7 90.2 74.7
4-Mar 146 108.7 0.07 132.7 0.03 133.8 0.14 90.7 0.92 72.9 0.56
Current viral load
,2 log copies/ml 163 109.2 134.1 134.8 91.1 73
.2 log copies/ml 25 111.8 0.37 137.1 0.58 136.5 0.92 87.5 0.29 75.4 0.47
* = p-value for test of trend; otherwise P-value derived from Wald test.
Multivariable linear regression model; marginal adjusted means for RNFL parameters were estimated at the mean value of covariates in the model.
Adjusted for age, gender, smoking status, mean arterial blood pressure, BMI, nadir and current CD4 count, ART regimen and all parameters displayed in table.
doi:10.1371/journal.pone.0073694.t004
Figure 3. Scatterplot showing temporal RNFL thickness vs. log
contrast sensitivity values.
doi:10.1371/journal.pone.0073694.g003
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disorders [31]. Therefore measurement of RNFL may also be a
useful novel predictor in this context.
Although the frequency of poor CS was markedly higher in
HIV-infected individuals compared to controls, the median visual
acuity between the two groups was the same and all participants
had visual acuity better than 20/40. Contrast sensitivity loss can be
present even when visual acuity and fields are relatively intact [32].
It is also a better predictor of mobility performance than visual
acuity [33]. These findings highlight that visual complaints from
HIV-infected individuals may be related to poor CS, and that
visual acuity testing (often performed as a baseline ‘screen’ by HIV
physicians to guide further referral) will often be normal.
Assessment of CS could be a useful aid in initial examination of
patients with symptoms suggestive of visual dysfunction.
In the context of accelerated aging and HIV, reduced thickness
of the RNFL in HIV-infected individuals compared to uninfected
counterparts of similar age might be expected as the RNFL thins
with increasing chronological age [12,13]. Other studies have
compared RNFL thickness in HIV-infected individuals with HIV-
seronegative controls, but it is difficult to make comparisons as
study populations differ in terms of demographic and HIV-related
characteristics as well as in the methods used to assess RNFL.
Thinning of the RNFL has been detected in HIV-infected
participants in the USA with low nadir CD4 count when
compared with HIV-infected individuals with higher nadir CD4
count and HIV-seronegative controls in using OCT [4,34].
Significant thinning of the RNFL in HIV-infected participants
(regardless of CD4 count) compared to uninfected controls, was
observed with confocal scanning laser tomography [35] whereas a
study from Brazil did not find a significant difference in RNFL
thickness between HIV- infected and uninfected participants using
OCT [36]. In our study, we did not observe an overall difference
in RNFL thickness between the two groups, nor we did we detect
associations related to CD4 count and RNFL thickness, although
we did detect mild associations with HIV viremia. It is therefore
difficult to place our study in the context of previous work, as the
epidemiology of HIV in sub-Saharan Africa is likely to be different
to that in other regions. In addition, the HIV and ART ‘trajectory’
may be at earlier stages compared to HIV cohorts in well-
resourced settings (where the majority of studies have been
conducted) thus, our findings may reflect those seen relatively early
on in chronic HIV infection.
Our findings suggest that ART duration is an important factor
in determining RNFL thickness (inferior and nasal quadrants) after
adjusting for age and other co-variates, and we have previously
shown that narrower retinal arterioles are associated with
increasing duration of ART, independently of age [15]. RNFL
thinning and retinal arteriolar narrowing may be related to early
vascular dysfunction in the nerve fibre layer, mediated by either
HIV infection or ART. This is further substantiated by our finding
that RNFL thinning was observed mainly in the superior and
inferior quadrants, where the majority of large retinal vessels are
located. Longitudinal studies are required to evaluate the
contribution of ART and HIV infection to possible accelerated
aging changes in the RNFL.
The association of detectable HIV viremia with an increase in
RNFL thickness in our study population may be biologically
plausible. Medzhitov [37] used the term ‘‘para-inflammation’’ to
describe an intermediate tissue adaptive response: infection and
injury lead to full inflammation, whereas chronic tissue stress
initiates mild low-grade ‘para’-inflammation, a mechanism which
attempts to maintain tissue homeostasis and monitor tissue
malfunction. However, chronic para-inflammation can lead to
disease progression and is thought to be an important process in
age-related retinal diseases [38]. Increased levels of HIV viremia
might initiate a para-inflammatory process in the retina, which
may manifest as increased thickness of the RNFL. Kalyani and
associates [3] have also reported greater RNFL thickness in a
subgroup of HIV-infected individuals in the USA. They suggested
that mitochondrial toxicity (mediated by HIV or ART) may cause
axonal damage to the RNFL, leading to an initial phase of swelling
before atrophy. Similar mechanisms are postulated in Leber’s
hereditary optic neuropathy (LHON), a mitochondrial disorder
where mitochondrial dysfunction leads to degeneration of retinal
ganglion cells and their axons in the optic nerve [39]. OCT
measurements in LHON patients show that RNFL thickness
increases in the pre-symptomatic stage, followed by a reduction
over time [40]. Additionally, we found that lower CS score was
associated with thinner RNFL in the temporal quadrant, a finding
also demonstrated by Kalyani and associates [3]. Anatomically,
this could reflect preferential damage to the small-calibre axons of
the maculopapillary bundle, similar to proposed mechanisms in
LHON [3,39].
A key strength of this study is the inclusion of an age/gender-
matched control group with a similar socio-demographic profile as
the HIV-infected individuals. By recruiting from the same
community, we aimed to reduce the likelihood of differential risk
exposure in line with the recommendation for careful study design
when investigating premature aging in HIV [41]. Moreover, this
allowed us to directly reference findings in HIV-infected individ-
uals to a comparable control population, rather than recourse to
normative data from other populations. As there are few data
relating to normative visual function or RNFL in African
populations, reference to other ethnic or geographical populations
could produce erroneous comparisons. Our study population is
also large compared to several studies of RNFL and visual function
in HIV, and we used the same OCT machine and operator for the
duration of the study to minimize potential variability in
measurements, which can occur with different OCT machines
and operators [42].
This study had some limitations. The study design means we
cannot infer whether HIV is causally related to poor CS function
or changes in RNFL, nor can a temporal relationship be
established. The measurement of CS is subjective, however we
adhered to standardized protocols (e.g. lighting, measurement
distance) and used the same chart and examiner in the same
location. Another potential limitation is that misclassification of
smoking and alcohol consumption may have occurred, with HIV-
infected participants wanting to demonstrate ‘healthy behaviour’
which could have led to confounding. Finally, in the context of
further defining the HIV-neuroretinal disorder it would have been
ideal to have data on visual fields and colour vision, however, this
initial data provide an informative basis from which to plan further
studies in this study population or region. Further investigations
such as micro-perimetry and retinal electrophysiology would also
help to elucidate possible mechanisms and pathways of HIV-
associated neuro-retinal disorder.
In summary, HIV-infected individuals in South Africa demon-
strate abnormal CS, and changes in RNFL thickness related to
viremic status. Longitudinal studies are needed to determine
whether changes in RNFL and systemic indicators such as frailty
predict change in visual function, and equally importantly, the role
of ophthalmic indicators in predicting the biologically aged
phenotype in chronic HIV infection.
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